Incidence, patterns, risk factors and clinical outcomes of intravenous acyclovir induced nephrotoxicity

Abdullah M. Al-Alawi a,b,* , Juhaina Salim Al-Maqbali c, Maria Al-Adawi b, Anan Al-Jabri b, Henrik Falhammar d,e,f

a Department of Medicine, Sultan Qaboos University Hospital, Muscat, Oman
b Internal Medicine Training Program, Oman Medical Specialty Board, Muscat, Oman
c Department of Pharmacy, Sultan Qaboos University Hospital, Muscat, Oman
d Department of Endocrinology, Karolinska University Hospital, Stockholm, Sweden
e Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
f Menzies School of Health Research, Darwin, NT, Australia

Abstract

Objectives: Acyclovir is approved to treat herpes simplex virus (HSV) type 1, type 2 and varicella-zoster virus. It is mainly eliminated via the kidneys, for which drug crystals accumulation might lead to nephrotoxicity. This study aimed to determine the incidence, risk factors, preventive measures, and clinical outcomes of acyclovir induced-nephrotoxicity.

Methods: This is a retrospective cohort study of patients >12 years of age at Sultan Qaboos University Hospital (SQUH) receiving IV acyclovir therapy between January 2016 and December 2020.

Results: Out of 191 included patients, 40 (20.1%) developed acyclovir induced-nephrotoxicity. Age (per year older: OR 1.04, 95 %CI 1.01–1.07), total duration of treatment (per day OR 1.19, 95 %CI 1.06–1.33), and concomitant use of vancomycin (OR 5.96, 95 %CI 1.87–19.01) were significant independent risk factors for acyclovir induced-nephrotoxicity development. Nine patients (4.5%) died during the same hospitalization, including those three patients who required renal replacement therapy (1.5%).

Conclusion: Frequent monitoring of kidney function for older patients with concurrent use of vancomycin and IV hydration is essential to prevent IV acyclovir induced-nephrotoxicity. Antimicrobial stewardship is a crucial method to reduce the duration of treatment with IV acyclovir as appropriate.

© 2022 The Author(s). Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Acyclovir was approved to treat herpes simplex virus (HSV) in 1982 (Barber et al., 2019). It is a purine nucleoside synthetic agonist that converts to an active metabolite called acyclovir triphosphate that exhibits antiviral activity against HSV type 1, HSV type 2 and varicella-zoster virus (Kłysik et al., 2020, Cortesi and Esposito, 2008). The primary route of elimination is via the kidneys through glomerular filtration and renal tubular secretion, with a half-life in the body ranging from 2 to 3 h and up to 20 h depending on renal function (Cortesi and Esposito, 2008, Dubrofsky et al., 2016). Renal intratubular deposition of acyclovir crystals or acyclovir direct tubular toxicity are major mechanisms behind nephrotoxicity in patients treated with intravenous (IV) acyclovir (Chang et al., 2016, Izzedine et al., 2005, Yildiz et al., 2013). Unlike IV acyclovir, oral acyclovir is not associated with an increased risk of nephrotoxicity (Lam et al., 2013). After the introduction of acyclovir into the clinical practice, acyclovir induced nephrotoxicity has been reported in 10–48% of the patients; however, in more recent years, the incidence has decreased to 18–21%, which might be linked to dose adjustment, adequate hydration and slow acyclovir infusion (Richelsen et al., 2018).

Pre-existing renal disease, obesity and hypertension were associated with an increased risk of acyclovir induced nephrotoxicity (Ryan et al., 2018, Barber et al., 2019, Richelsen et al., 2018, Lee et al., 2018, Yildiz et al., 2013). Also, prolonged duration of treatment concomitant use of nephrotoxic medications is associated with increased risk of acyclovir induced
nephrotoxicity (Yalcinkaya et al., 2021). Improving intravenous hydration is a protective measure against acyclovir induced nephrotoxicity (Dubrofsky et al., 2016).

Studies from the Middle Eastern Region addressing acyclovir induced nephrotoxicity are scarce. Therefore, this study aims to assess the incidence, risk factors, preventive measures, and clinical outcomes of acyclovir induced nephrotoxicity at the largest tertiary centre in Oman.

2. Methodology

2.1. Study design and setting

This retrospective cohort study included all adult patients admitted to Sultan Qaboos University Hospital (SQUH) between January 1st 2016, and December 31st 2020 and treated with IV acyclovir for ≥24 h. We included all admitted adults patients of age ≥12 years old. In contrast, we excluded patients younger than 12 years, patients with haematological or solid organ malignancies, patients on renal replacement therapy, and patients lacking follow up data. Patients with malignancies were not included due to the complexity of diseases, prolonged admissions, and the presence of several other potential causes for nephrotoxicity.

The study was approved by the Medical Ethics Committee of the College of Medicine and Health Sciences at SQUH (REF. NO. SQU-EC/318/2020 MREC #2339).

2.2. Data collection

The following variables were collected: demographic data (age, sex, weight, and height); information on the indication for acyclovir; relevant comorbidities (diabetes mellitus, hypertension, heart failure, and chronic kidney disease (CKD)); information on IV hydration; information on dose and duration of IV acyclovir treatment; concomitant use of relevant medications including non-steroidal anti-inflammatory drugs (NSAIDs), diuretics, angiotensin-converting enzyme inhibitors (ACEIs), and angiotensin receptor blockers (ARBs), vancomycin, or aminoglycoside; information on the use of contrast medium; creatinine measurements (at baseline before starting acyclovir therapy, at the peak after and during the acyclovir therapy, and latest reading prior to hospital discharge); data on acyclovir induced-nephrotoxicity and clinical outcome (need for renal replacement therapy or death).

2.3. Definitions

Acyclovir dosage regimen was calculated based on mg/kg/dose (ranging from 5 –10 mg/kg/ dose every 8 to 24 h depending on patient creatinine clearance expressed in ml/minutes/1.73 m²), to be infused over 1 h while maintaining adequate hydration of the patient.

Primary outcome is the incidence of AKI due to acyclovir treatment. Acute kidney injury (AKI)/acyclovir induced-nephrotoxicity and CKD were defined according to Kidney Disease Improving Global Outcomes (KDIGO) criteria (Levey et al., 2005, Khwaja, 2012), which include an increase in serum creatinine ≥26.5 μmol/l within 48 h or 50% from baseline or urine output less than 0.5 mL/kg/h for 6 h. However, due to a lack of data on urine output, we used the serum creatinine level to define acyclovir induced nephrotoxicity.

2.4. Microbiological definitions

Presumed meningoencephalitis: patient presented with symptoms and signs likely caused meningoencephalitis in the absence of other explanation. Lumbar puncture was not obtained due to the presence of contraindication or due to lack of consent.

HSV encephalitis: HSV encephalitis was confirmed using polymerase chain reaction (PCR) of cerebrospinal fluid analysis.

Varicella-zoster infection: diagnosed with the presence of fever and the typical dermatological manifestation of chickenpox or shingles.

2.5. Statistical analyses

Categorical variables were reported as numbers and percentages. Continuous variables were expressed as mean ± SD if normally distributed or median (IQR) if non-normally distributed. Continuous variables (e.g. age, the dose of acyclovir) between the two groups were compared using the student t-test for normally distributed variables or Wilcoxon rank-sum for not normally distributed variables. Chi-square test or Fisher’s exact were used to assess the association between categorical variables as appropriate. Variables with a p-value < 0.25 on univariate were included in the multivariable logistic regression analysis. Statistical calculations were performed using the Stata v. 16.1 software package (StataCorp).

3. Results

One hundred ninety-nine patients met our inclusion criteria. The mean age was 45.8 ± 19.7 years, and 49.8% were men. The most common comorbidities were hypertension (33.2%), diabetes mellitus (24.1%), CKD (13.9%), and heart failure (6.0%). Presumed meningoencephalitis was the most common indication (87.5%) for IV acyclovir. The average treatment duration was 5.0 ± 4.0 days, and most of the patients (80.8%) received IV hydration. The most common concurrent medications were NSAIDs (29.6%) and vancomycin (28.6%). IV contrast medium was received by 41.2% during the same hospital admission (Table 1).

In total, 40 patients (20.1%) developed acyclovir induced-nephrotoxicity. Univariate analysis revealed that age (p = 0.028), diabetes mellitus (p = 0.027), concurrent use of vancomycin (p = 0.003), aminoglycoside (p = 0.043), higher baseline creatinine value (p = 0.010), and death (p < 0.001) were significantly higher in the acyclovir induced-nephrotoxicity group (Table 1). While multivariate regression analysis showed that only age, total treatment duration, and concomitant vancomycin use sustained significant independent risk factors for acyclovir induced-nephrotoxicity development (Table 2).

Renal replacement therapy was required by three patients (1.5%), and nine patients (4.5%) died during the same hospitalization, including all those who required renal replacement therapy.

4. Discussion

We found that the incidence of acyclovir induced nephrotoxicity in hospitalized patients who received acyclovir was 20.1% which is similar to some of the previously reported studies (Lee et al., 2018, Kim and Byun, 2015, Ryan et al., 2018, Pacheco et al., 2005). Older age, longer duration of treatment, and concomitant vancomycin use were independent risk factors for acyclovir induced-nephrotoxicity development. This is the first-time age has been associated with acyclovir induced-nephrotoxicity development. Three patients required renal replacement therapy, and they died during the same hospitalization. Overall, mortality was higher in the acyclovir induced-nephrotoxicity group.

Acyclovir is an effective therapeutic agent for herpes simplex and varicella-zoster viruses infections. Around 60–90% of acyclovir is excreted unmetabolized via the kidneys, for which drug crystal-
Multi-regression analysis of risk factors for developing IV acyclovir-induced nephrotoxicity.

| Characteristic, percentage (%) unless specified otherwise | Total cohort (n = 199) | Non-acyclovir induced-nephrotoxicity group (n = 159) | Acyclovir induced-nephrotoxicity group (n = 40) | P-value |
|-----------------------------------------------------------|------------------------|--------------------------------------------------|-------------------------------------------------|---------|
| Age (year ± SD)                                           | 45.8 ± 19.7            | 44.2 ± 20.1                                      | 51.9 ± 16.6                                     | 0.028   |
| Male                                                      | 99 (49.8)              | 79 (49.7)                                        | 20 (50%)                                        | 1.000   |
| Weight (kg ± SD)                                          | 70.1 ± 21.6            | 69.0 ± 22.3                                      | 76.1 ± 17.8                                     | 0.104   |
| Height (cm ± SD)                                          | 157.2 ± 16.7           | 157.3 ± 17.5                                     | 156.9 ± 12.6                                    | 0.9350  |
| Diabetes mellitus                                         | 48 (24.1)              | 33 (20.8)                                        | 15 (37.5)                                       | 0.0271  |
| Hypertension                                              | 66 (33.2)              | 48 (30.2)                                        | 18 (45.0)                                       | 0.058   |
| CKD                                                       | 29 (13.9)              | 21 (13.2)                                        | 8 (20.0)                                        | 0.220   |
| Heart failure                                             | 12 (6.0)               | 8 (5.0)                                          | 4 (10.0)                                        | 0.220   |
| Presumed meningocoeplexanil                              | 133 (67.5)             | 98 (61.7)                                        | 35 (87.5)                                       | 0.23    |
| HSV esceplexanil                                          | 28 (14.1)              | 26 (16.4)                                        | (5.0)                                           | 0.07    |
| Other HSV infection                                       | 1 (0.5)                | 1 (0.63)                                         | 0                                               |         |
| Varicella-zoster infection                                | 37 (18.6)              | 34 (21.4)                                        | 3 (7.5%)                                        | 0.06    |
| Total dosage (mg, IQR)                                    | 6750 (3750–12400)      | 7000 (3750–12400)                                | 5530 (3750–11900)                               | 0.9376  |
| Total duration of treatment (days ± SD)                   | 5.0 ± 4.1              | 4.6 ± 3.7                                        | 6.4 ± 5.2                                       | 0.0577  |
| IV hydration                                              | 161 (80.9%)            | 130 (81.8)                                       | 31 (77.5)                                       | 0.540   |
| Vancomycin                                                | 57 (28.6%)             | 38 (23.9)                                        | 19 (47.5%)                                      | 0.03    |
| Aminoglycoside                                            | 3 (1.5)                | 1 (0.6)                                          | 2 (5.0)                                         | 0.043   |
| Diuretics                                                 | 31 (15.6)              | 21 (13.2)                                        | 10 (25.0)                                       | 0.066   |
| ACEI/ARB                                                  | 30 (15.1)              | 24 (15.1)                                        | 6 (15.0)                                        | 0.988   |
| NSAIDs                                                    | 59 (29.6%)             | 47 (29.6)                                        | 12 (30.0)                                       | 0.957   |
| Contrast media                                            | 82 (41.2)              | 64 (40.3)                                        | 18 (45)                                         | 0.585   |
| Baseline creatinine value (umol/L, IQR)                   | 74 (52–93)             | 68 (51–87)                                       | 82 (52–113)                                     | 0.0101  |
| Requirement for renal replacement therapy                 | 3 (1.5)                | 0 (0)                                            | 3 (7.5)                                         | 0.001   |
| Death                                                     | 9 (4.5)                | 0 (0)                                            | 9 (22.5)                                        | <0.001  |

SD, standard deviation; IQR, interquartile range; CKD: chronic kidney disease; HSV: herpes simplex virus; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin II receptor blocker; NSAIDs: non-steroidal anti-inflammatory drug.

SD, standard deviation; IQR, interquartile range; CKD: chronic kidney disease; HSV: herpes simplex virus; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin II receptor blocker; NSAIDs: non-steroidal anti-inflammatory drug.

Table 1
Demographic, clinical and laboratory data and health outcomes of patients treated with IV acyclovir.

5. Conclusion

The incidence of acyclovir-induced nephrotoxicity was around 20%. Older age, longer duration of treatment and concomitant use of vancomycin were significantly associated with increased acyclovir induced-nephrotoxicity risk. Kidney function monitoring and hydration are essential elements for patients receiving IV acyclovir. Antimicrobial stewardship is an essential step to avoid unnecessary coadministration of acyclovir and vancomycin and to shorten the duration of acyclovir as clinically appropriate.
Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

Barber, K.E., Wagner, J.L., Stover, K.R., 2019. Impact of obesity on acyclovir-induced nephrotoxicity. Open Forum Infect. Dis. 6, ofz121.
Catalano, C., Conforto, L., 2005. Valaciclovir-related neuro- and nephrotoxicity in two geriatric patients. G. Ital. Nefrol. 22 (Suppl 31), S132–S134.
Chang, Y.H., Tseng, J.Y., Chen, C.Y., Sung, P.L., Yeh, C.C., Yang, M.J., 2016. Acyclovir-induced nephrotoxicity in a pregnant woman with chickenpox. Taiwan J. Obstet. Gynecol. 55, 618–619.
Cortesi, R., Esposito, E., 2008. Acyclovir delivery systems. Expert. Opin. Drug. Deliv. 5, 1217–1230.
Dubrofsky, L., Kerzner, R.S., Delaunay, C., Kolenda, C., Pepin, J., Schwartz, B.C., 2016. Interdisciplinary systems-based intervention to improve IV hydration during parenteral administration of acyclovir. Can. J. Hosp. Pharm. 69, 7–13.
Izzedine, H., Launay-Vacher, V., Deray, G., 2005. Antiviral drug-induced nephrotoxicity. Am. J. Kidney. Dis. 45, 804–817.
KHWAJA, A. 2012. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin. Pract., 120, c179–84.
Kim, S., Byun, Y., 2015. Comparison of renal function indicators according to hydration volume in patients receiving intravenous acyclovir with CNS infection. Biol. Res Nurs 17, 55–61.
Klysiak, K., Pietraszek, A., Karewicz, A., Nowakowska, M., 2020. Acyclovir in the treatment of herpes viruses - a review. Curr. Med. Chem. 27, 4118–4137.
Lee, E.J., Jang, H.N., Cho, H.S., Bae, E., Lee, T.W., Chang, S.-H., Park, D.J., 2018. The incidence, risk factors, and clinical outcomes of acute kidney injury (staged using the RIFLE classification) associated with intravenous acyclovir administration. Ren. Fail. 40 (1), 687–692.
Levey, A.S., Eckardt, K.-U., Tsukamoto, Y., Levin, A., Coresh, J., Rossert, J., Zeeuwe, D.D. E., Hostetter, T.H., Lameire, N., Eknayan, G., 2005. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney. Int. 67 (6), 2089–2100.
McLachlan, A.J., Pont, L.G., 2012. Drug metabolism in older people—a key consideration in achieving optimal outcomes with medicines. J. Gerontol. A. Biol. Sci. Med. Sci. 67, 175–180.
Pacheco, L.R., Tavares, H.M., Moysés Neto, M., Dantas, M., Rocha, L.S., Ribeiro, K.M., Figueiredo, J.F., 2005. [Acute renal failure related to intravenous acyclovir]. Rev. Assoc. Med. Bras. (1992), 51, 275–278.
Richelsen, R.K.B., Jensen, S.B., Nielsen, H., 2018. Incidence and predictors of intravenous acyclovir-induced nephrotoxicity. Eur. J. Clin. Microbiol. Infect. Dis. 37, 1965–1971.
Ryan, L., Heed, A., Foster, J., Valappil, M., Schmid, M.L., Duncan, C.J.A., 2018. Acute kidney injury (AKI) associated with intravenous aciclovir in adults: Incidence and risk factors in clinical practice. Int. J. Infect. Dis. 74, 97–99.
Sagawa, N., Tsurutani, Y., Nomura, K., Okuyama, T., Kondo, M., Sata, A., Miyao, M., Mizuno, Y., 2014. Acyclovir-induced neurotoxicity and acute kidney injury in an elderly diabetic patient treated with valacyclovir: report of a case. Nihon Ronen Igakkai Zasshi. 51, 581–585.
Whitley, R.J., Blum, M.R., Barton, N., de Miranda, P., 1982. Pharmacokinetics of acyclovir in humans following intravenous administration. A model for the development of parenteral antivirals. Am. J. Med 73, 165–171.
Yalcinkaya, R., Oz, F.N., Kaman, A., Aydin Teke, T., Yasar Durmus, S., Celikkaya, E., Tanir, G. 2021. Factors associated with acyclovir nephrotoxicity in children: data from 472 pediatric patients from the last 10 years. Eur. J. Pediatr., 180, 2521–2527.
Yalcinkaya, R., Oz, F.N., Kaman, A., Aydin Teke, T., Yasar Durmus, S., Celikkaya, E., Tanir, G. 2021. Factors associated with acyclovir nephrotoxicity in children: data from 472 pediatric patients from the last 10 years. Eur. J. Pediatr., 180, 2521–2527.
Yildiz, C., Ozsurekci, Y., Gucer, S., Cengiz, A.B., Topaloglu, R., 2013. Acute kidney injury due to acyclovir. CEN. Case. Rep 2, 38–40.